Guangzhou Zhiling Biomedical

Guangzhou Zhiling Biomedical is a clinical-stage biotechnology company based in Guangzhou, China, specializing in the development of advanced cell therapies for oncology. Founded in 2016, the company focuses on Tumor-Infiltrating Lymphocyte (TIL) technology to treat solid tumors. Its lead candidate, ZLT-001, is a second-generation TIL cell drug that has received Investigational New Drug (IND) approval from the NMPA for the treatment of metastatic and recurrent cervical cancer. Zhiling Biomedical has been recognized as a "Future Unicorn" and a top biotech innovator in the Guangdong-Hong Kong-Macao Greater Bay Area. The company operates as part of the Keyuan Huaji group and maintains research and manufacturing facilities in the Guangzhou Development Zone.